Search
med
duoTM

A platform for advanced multi-target testing with independent antigen and antibody detection enabling interference-free results.

One Platform. Any Combination.

The MEDDUO™ platform is designed to generate multiple results within the same device. It supports defined combinations of antibody and antigen targets as well as multiplex detection of up to eight (8) antibody or antigen analytes within one assay. The platform incorporates a dual-window read-out design that physically separates antigen and antibody detection pathways. This separation enables independent assay workflows, supports clear result interpretation, and prevents cross-interference between antigen- and antibody-based assays.

  • Immediate results

    No waiting time, results do not vanish.

  • Reliable accuracy

    Achieves high TP testing performance across multiple specimen matrices.

  • Antigen and antibody detection

    Dual-chamber design enables interference-free antigen and antibody results.

  • No equipment or refrigeration required

    Stores at room temperature (2–30 °C / 35–86 °F) with a 12-month shelf life.

  • Easy to use and interpret

    Simple procedure with instant, easy-to-read results, no special training required.

  • Ideal for any setting

    Works with serum, plasma, and whole blood (venipuncture or fingerstick)

medduo side

Dual-Window Formats

In contrast to conventional single-window RVF cartridges, the MEDDUO™ platform utilizes differentiated buffer volumes, multiple reagent vials, and two independent read-out windows. This architecture enables flexible assay configuration while maintaining separation of detection chemistries. The two read-out windows can be configured in different modes:

t1 t8 ab
Dual Antibody Testing

both windows configured for antibody detection

t1 t8 ag
Dual Antigen Testing

both windows configured for antigen detection

t1 t4 ab t5 t8 ag
t1 t8 ag
Dual Antigen Testing

both windows configured for antigen detection

From sample to results

in three simple Steps

Testing doesn’t have to be complicated. Our intuitive three-step process ensures instant, consistent results with minimal effort. 
In this example, the right read-out window is configured for antigen detection and the left read-out window for antibody detection.

blood
Pour specimen

Add whole blood specimen to buffer in vial 1. 
Perform this step once only.

medduo a gen1
Add sample to lyophilized vial

Using the supplied disposable pipette, add 10 drops from Step 1 to the lyophilize vial, mix to dissolve.

medduo a gen step2
Pour lyophilized content

Pour the contents of the lyophilized vial onto the right reaction window.

medduo blood
Pour specimen

Add whole blood specimen to buffer in vial 1. 
Perform this step once only.

medduo step3
Cap and Pour buffer

Place the InstantGold™ cap on the left reaction window and pour buffer onto it.

For a similar procedure, watch the Miriad® multiLinx HIV/HCV/TP Antibody & HBsAg/HBeAg Antigen video (Youtube, 5:05 min).

medduo2
Pour specimen

Add serum, plasma specimen to buffer in vial 1. Perform this step once only.

ps2
Add specimen

Add specimen and mix to reconstitute the lyophilized material until fully dissolved.

medduo serum
Pour contents

Pour the contents of the lyophilized vial onto the right reaction window.

ps
Add sample

Pour the remaining specimen from vial 1 onto the left reaction window.

medduo step3
Cap and Pour buffer

Place the InstantGold™ cap on the left reaction window and pour buffer onto it.

For a similar procedure, watch the Miriad® multiLinx HIV/HCV/TP Antibody & HBsAg/HBeAg Antigen video (Youtube, 5:05 min).

Explore your options with us

Interested in learning more about the MEDDUO™ platform, developing a custom assay, or exploring new testing concepts? We welcome your inquiry. Please contact us for further information.

Frequently Asked Questions

How does the dual-chamber technology improve result clarity?

Dual-chamber technology separates antigen and antibody reactions into two independent test areas, preventing them from affecting each other. In some single-chamber assays that use biotin-streptavidin binding chemistry, elevated biotin (vitamin B7) levels in patient samples can disrupt assay performance and lead to unclear or inaccurate results. By physically separating antigen and antibody detection into independent chambers, MEDDUO™ reduces the risk of such interference and helps ensure clear, reliable, and interpretable results for combination antigen/antibody testing.

How does MEDDUO™ differ from Multiplo®?

Multiplo® provides a single integrated readout for multi-parameter infection screening, ideal for broad public health testing. MEDDUO™, by contrast, uses a dual-window system that separates antigen and antibody detection, providing clear results without cross-interference and making it the preferred platform for next-generation antigen/antibody combination assays.

What tests are currently available on the MEDDUO™ platform?

The MEDDUO™ platform is MedMira’s dual-window RVF cartridge architecture. MultiLinx™ assays represent multiplex test configurations that may be implemented on MEDDUO™ or standard RVF cartridges. Certain RUO assays such as HIV-HCV-TP-HBsAg-HBeAg distributed through partners are based on licensed MedMira technology and represent earlier-generation implementations.

Is the MEDDUO™ platform limited to specific analyte combinations?

No. The MEDDUO™ platform is designed as a configurable system that supports a wide range of antibody and antigen combinations. Assay configurations can be adapted based on target selection and application requirements. For further information or specific assay inquiries, please contact us.
Contact us

What is RVF technology™?

RVF (Rapid Vertical Flow) is a flow-through technology that captures specific biomarkers from blood, serum, or plasma samples on a specialized membrane, delivering instant visual results.
Learn more

Privacy Policy

Last updated: April 20, 2026

MedMira Inc. (“MedMira”, “we”, “us”, or “our”) is committed to protecting personal information in accordance with applicable privacy laws, including the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada, as well as applicable United States and international privacy requirements.

This Privacy Policy describes how we collect, use, disclose, and safeguard personal information through our website. Our website is primarily informational in nature and does not provide user accounts, applications, or diagnostic services.

Terms And Conditions Of Use

Please Read These Terms Carefully Before Using This Site. This website is provided by MedMira Inc. (MedMira) and may be used for informational purposes only. By using the site or downloading materials from the site, you agree to abide by the terms and conditions set forth in this notice. If you do not agree to abide by these terms and conditions do not use the site or download materials from the site.

Subscribe
Join our newsletter

Receive company updates, regulatory milestones, and event announcements.

By subscribing, you agree to our Privacy Policy and consent to receive updates.

Committed to quality
Certified & Proven Quality

Our quality management system is ISO 13485:2016 certified, compliant with the United States Food and Drug Administration’s current Good Manufacturing Practices (cGMP: Quality System Regulation Part 820 of CFR Title 21, Volume 8), European Union’s Directive 98/79/EC on in vitro diagnostic medical devices, and Health Canada Medical Device Regulations (SOR/98-282).

Additionally, we adhere to ISO 14971 (Application of Risk Management to Medical Devices) and ISO 2859 (Sampling Procedures for Inspection by Attributes). Certification and compliance to these requirements attests to our ability to maintain the highest standard of quality in medical device manufacturing, product development and corporate conduct.

Our products have been approved by regulators and UN agencies worldwide.

FDA

Health Canada

International Trade Centre (ITC)

Pan American Healtch Organization (PAHO)

UN Development Programme (UNDP)

UN Office for Project Services (UNOPS)

UN Office at Vienna (UNOV)

UN Population Fund (UNFPA)

United States Agency for International Development (USAID)

CFO & Head of Commercialization

Markus Meile

Markus joined MedMira in 2010, and moved into the role of Chief Financial Officer in 2014.

He previously served on the Company’s Board of Directors, as a member of the Audit Committee, and as the Senior Director of International Markets.

Prior to joining MedMira, Markus worked with a number of financial institutions in Switzerland, England, and Hong Kong. He holds a BSc from Royal Holloway University of London and has studied business management, strategic planning, investment and accounting at business school in Zurich. Previously, Markus worked in the medical device industry in Africa, Asia Pacific, and Europe.

He will combine his financial expertise with his broad range of international business knowledge to build financial and corporate strategies supporting MedMira’s continuing growth and increasing shareholder value.

Director of the Audit Committee, Nomination and Compensation Committee

Jianhe Mao

Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland. Unipec focuses on helping European companies enter the Chinese market, through operational restructuring and ownership and management optimization.

In addition to leading Unipec, Mr. Mao is involved in several industrial projects and start-up ventures including Monsatec AG, a new company bridging the gap between laboratories and clinics with a cold plasma medical device. He serves on the boards of several European companies and is regarded as a trusted expert in legal cases, corporate corruption, operational turnarounds, and mergers and acquisitions.

Mr. Mao began his career as a project engineer and has gained experience in business development and real estate investment. He holds M.E. from Ruhr University Bochum.

CEO, Co-Founder & Co-Inventor

Hermes Chan, D.Sc. (h.c.)

Hermes Chan, our Chief Executive Officer and Co-Founder, leads our passionate and committed team in driving the strategic direction and growth of MedMira.

Hermes, who was named BioScience Innovator of the Year by The Economist in 2007, is the inventor of our patented rapid flow-through diagnostic technology platform.

Since the company’s inception in 1994 Hermes has held progressively senior management roles including Research Scientist, General Manager, Senior Vice President, and Chief Operating Officer.

Prior to creating MedMira, Hermes worked with another Canadian biotechnology company in the diagnostics research sector.

Chair member of the Audit Committee, Nomination and Compensation Committee

Steven Cummings

Mr. Steven Cummings is the Founder & President of Cambridge Financial Services, one of the leading full service accounting, tax, and business advisory firms in Nova Scotia.

Under Mr. Cummings leadership, Cambridge Financial has earned an enviable reputation among businesses and industry for a commitment to high standards. Along with his leadership responsibilities at Cambridge Financial Services, Mr. Cummings was engaged as MedMira’s interim Chief Financial Officer in 2007.

With more than 30 years of financial and entrepreneurial experience, Mr. Cummings is a frequent guest speaker on issues surrounding provincial taxation, taxation of seniors, and business ownership

Intellectual property

China

ZL02819646.5

Rapid Diagnostic Device and Assay

Intellectual property

European union

EP1417489

Rapid Diagnostic Device and Assay

EP1328811

HCV Mosaic Antigen Composition (2021)

Intellectual property

USA

9,164,087

Rapid Diagnostic Device, assay and multifunctional Buffer

9,086,410

Downward or vertical flow diagnostic device and assay

8,025,850

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,287,817

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,586,375

Rapid Diagnostic Device, Assay and Multifunctional Buffer

7,531,362

Rapid Diagnostic Device, Assay and Multifunctional Buffer

D706945

Diagnostic Device

D706466

Diagnostic Device

11,353,450

Analyte Detection Using Raman Spectroscopy

Intellectual property

Canada

CA2,493,616

Rapid Diagnostic Device, Assay and Multifunctional Buffer

CA2,740,902

Downward or Vertical Flow Diagnostic Device and Assay

CA2,949,634

Analyte Detection Using Raman Spectroscopy

MiROQ Vision

Handheld Device

A future concept built on the same MIROQ technology, designed to deliver lab-grade precision in the palm of your hand.

We envision a future where testing can happen anywhere, anytime – from hospitals and clinics to remote regions or even at home – enabling early disease detection and turning knowledge into real impact. No large equipment or complex infrastructure required.

For: Doctor’s offices, small and mobile clinics

Future application: Home use

Connectivity: Bluetooth, Wifi and USB